Hyperhidrosis Treatment Market By Global Top Key Players, Share, Size, Demand, Opportunities, Sale Area, Revenue Analysis Forecast Outlook 2028
Hyperhidrosis Treatment Market to Witness a Robust Growth
in the Upcoming Years
Market Highlights
According to MRFR analysis, Hyperhidrosis
Treatment Market is expected to register a CAGR of 6.07% during the
forecast period and is expected to reach USD 1,925.9 Million by 2025.
Hyperhidrosis is a condition in which the affected person
experiences excessive sweating. Hyperhidrosis can be divided into two
types—primary hyperhidrosis and secondary general hyperhidrosis. Primary
hyperhidrosis is the most common type, with 80% of people are affected by it.
The growth of the global Hyperhidrosis Treatment Market is
driven by various factors such as rising research and development activities
for developing novel approaches for hyperhidrosis treatment, increasing
awareness activities and campaigning about hyperhidrosis, upsurge in the usage
of botulinum toxin injections, advancement in the therapeutic approaches such
as laser and electronic therapy, increasing support by public and private
companies. On the other hand, unavailability of the permanent clonidine for
hyperhidrosis, and expensive treatment options are some factors that may
hinder the growth of the hyperhidrosis market to an extent.
Get Sample Reports: https://www.marketresearchfuture.com/reports/hyperhidrosis-treatment-market-8475
Key Players
Some of the key players in the global hyperhidrosis
treatment market are Allergan PLC (Ireland), Brickell Biotech Inc. (US),
Cynosure (US), Dermadry Laboratories inc. (Canada), Dermira Inc. (US),
GlaxoSmithKline PLC (UK), Miramar Labs, Inc. (US), Sesderma (Spain), and
Ulthera Inc. (US).
The global hyperhidrosis treatment market is currently
scattered, and no particular player is dominating the market. This is mainly
due to the different types of therapeutic approaches being used to treat the
disorder. However, few key players are involved in the new product launches and
other developments to strengthen their market positions. For instance, in June
2018, Dermira received the Food and Drug Administration (FDA) approval for
Qbrexza (glycopyrronium), a topical treatment for primary axillary
hyperhidrosis (excessive underarm sweating).
Segmentation
The global hyperhidrosis treatment market has been segmented
based on type, treatment, and end-user.
·
The market, based on type, has been
divided into primary hyperhidrosis and secondary generalized hyperhidrosis. The
primary hyperhidrosis segment is likely to hold the largest during the review
period due to the large population being affected by the primary hyperhidrosis.
Besides being largest, it is also predicted to be the fastest-growing segment
due to the increasing awareness about the condition and increasing patient
population opting for the aesthetic procedures in order to manage the medical
condition.
·
on the basis of treatment, into botulinum
toxin injections, topical treatment, surgical treatment, oral medication,
microwave therapy, and others. The topical treatment segment is expected to
hold the maximum share of the market owing to the wide acceptance of the
topical products, convenience of use, and fewer risks compared to other
therapies. The botulinum toxin injections segment is expected to be the
fastest-growing due to the rising awareness about the treatment and high per
capita disposable incomes in developed countries.
·
The end-users of the market are
dermatology clinics, ambulatory surgery centers, payers/patients, and others.
The payers/patients segment is expected to hold the largest share of the
market. This is attributed to factors such as patient’s easy access to the
topical treatments, high commercial availability, and convenience in use as
compared to other treatment options. The dermatology clinics segment is
expected to be the fastest growing owing to the increasing adoption of
aesthetic procedures for the management of hyperhidrosis.
Regional Analysis
The market has been divided, by region, into the Americas,
Europe, Asia-Pacific, and the Middle East & Africa. The Americas is
expected to be the largest market owing to the increased awareness about
hyperhidrosis treatment and high per capita disposable incomes. The
hyperhidrosis treatment market in the Americas has further been branched into
North America and Latin America, with the North American market divided into
the US and Canada. The European hyperhidrosis treatment market has been
categorized as Western Europe and Eastern Europe. The Western European market
has further been divided as Germany, France, the UK, Italy, Spain, and the rest
of Western Europe. The hyperhidrosis treatment market in Asia-Pacific has been
segmented into Japan, China, India, South Korea, Australia, and the rest of
Asia-Pacific. Due to the rising per capita healthcare expenditure and growing
awareness towards the management of hyperhidrosis, the market in Asia-Pacific
is expected to be the fastest-growing. The hyperhidrosis treatment market in
the Middle East & Africa has been divided into the Middle East and Africa.
Browse Full Reports: https://www.marketresearchfuture.com/reports/hyperhidrosis-treatment-market-8475
Related Report-
Ticagrelor
Market Research Report - Global Forecast till 2027
Precision
Medicine Market Research Report - Global Forecast till 2027
About US:
Market Research Future (MRFR) enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment